SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ONC

BeOne Medicines Ltd. (NASDAQ:ONC)

CH · Delayed Price · Currency is USD
Also listed: BGNEHealthcare · Biotechnology
$390.94-$8.76 (-2.19%)
 
Market cap
$41.8B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 3, 2016
Market Cap$41.78B+12.4%
Revenue (ttm)$6.61B+32.9%
Net Income$915.57M+1235.6%
EPS$8.57+379.2%
Shares Out106.86M
PE Ratio45.62
Forward PE37.01
Dividendn/a
Ex-Dividend Daten/a
Volume356,778
Open$391.75
Previous Close$399.70
Day's Range$389.77 - $399.17
52-Week Range$253.95 - $424.73
Beta0.52
AnalystsBuy
Price Target$426.50(+9.10%)
Earnings DateFeb 25, 2027

About ONC

BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.

Address
Aeschengraben 27, Basel, PA, 4051, CH
Market Cap
41.78 billion
Employees
12,000
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$23.71M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
6 Buy0 Hold0 SellAvg target $420.14 (+4.1%)

6 firms rating ONC in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From ONC’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.19%
5 Days
-6.21%
1 Month
+1.16%
6 Months
+26.26%
1 Year
+12.43%

$ONC stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ONC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ONC's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ONC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ONC Revenue by Segment or Geography

$4.33BTotal
Product revenue gross$2.44B56.31%
Product revenue net$1.89B43.69%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ONC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ONC from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ONC

IBBiShares Biotechnology ETF$261.45M
FBTFirst Trust NYSE Arca Biotechnology Index Fund$108.97M
CGGOCapital Group Global Growth Equity ETF$96.93M
CGGECapital Group Global Equity ETF$26.16M
CGNGCapital Group New Geography Equity ETF$19.23M
CGIECapital Group International Equity ETF$16.48M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ONC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
97
News & Sentiment
20% of score
72

News check: Partnership expansion and Q3 earnings call suggest operational momentum; stock performance mention indicates market confidence in oncology focus.

Recent Insider Activity

Buys
0
Sells
22
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-39.0 since Aug 21
0255075100Aug 21 — Insider Score 39.0Aug 22 — Insider Score 39.0Aug 23 — Insider Score 39.0Aug 24 — Insider Score 39.0Aug 25 — Insider Score 39.0Aug 26 — Insider Score 38.0Aug 27 — Insider Score 38.0Aug 28 — Insider Score 38.0Aug 29 — Insider Score 38.0Aug 30 — Insider Score 38.0Aug 31 — Insider Score 38.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 25.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CANCTema Oncology ETF4.34%
FBTFirst Trust NYSE Arca Biotechnology Index Fund3.84%
BBHVanEck Biotech ETF3.00%
BGGGBaillie Gifford Long Term Global Growth ETF2.89%
AGNGGlobal X - Aging Population ETF2.82%
IBBiShares Biotechnology ETF2.42%
XUSMMarketDesk International Momentum ETF2.23%
NSINational Security Emerging Markets Index ETF1.88%
ESIMEventide International ETF1.56%
EDGE.TOEvolve Innovation Index Fund1.49%
BGEGBaillie Gifford Emerging Markets ETF1.28%
IBBQInvesco Nasdaq Biotechnology ETF0.96%

Weight is the stock’s share of each fund’s holdings.